GlassScriptPhysician profile
Norman J Sfeir
NPI 1972567741
$5,810.98
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,038 · 2021: $1,492 · 2022: $1,522.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,470.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,075.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $806.15 | 2019-2022 | |
| Abbott Laboratories | $404.86 | 2019-2020 | |
| Amgen INC. | $241.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $225.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.24 | 2019-2022 | |
| Grifols USA, LLC | $157.00 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $146.91 | 2019-2022 | |
| Philips North America LLC | $124.88 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $105.06 | 2019-2022 | |
| Genentech USA, INC. | $104.17 | 2019 | |
| Genzyme Corporation | $103.28 | 2021-2022 | |
| Mylan Specialty L.P. | $100.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $79.39 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75.78 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $66.12 | 2019 | |
| Insmed, INC. | $46.18 | 2021 | |
| Alexion Pharmaceuticals, INC. | $44.49 | 2019 | |
| Astellas Pharma US INC | $31.87 | 2021 | |
| Esperion Therapeutics, INC. | $28.72 | 2021 | |
| Baxter Healthcare | $23.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.80 | 2020 | |
| Shire North American Group INC | $19.61 | 2019 | |
| Circassia INC. | $18.94 | 2019 | |
| Gilead Sciences, INC. | $16.76 | 2019 | |
| Inogen, INC. | $15.73 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.01 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Sfeir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.